PXL 770

Drug Profile

PXL 770

Alternative Names: PXL-770

Latest Information Update: 18 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Poxel
  • Class Antihyperglycaemics
  • Mechanism of Action AMP activated protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 21 Sep 2017 Poxel plans to initiate a proof-of-concept trial in 2018
  • 15 Sep 2016 Preclinical data from a study in Type 2 diabetes mellitus released by Poxel
  • 20 Jun 2016 Pharmacokinetics and adverse evets data from the first stage of phase I trial in Type-2 diabetes released by Poxel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top